Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor ...Middle East

PR Newswire - News
COPENHAGEN, Denmark and SHANGHAI, Aug. 20, 2024 /PRNewswire/ -- Adcendo ApS ("Adcendo") and Multitude Therapeutics Inc. ("Multitude") jointly announced today that they have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC)...

Hence then, the article about adcendo aps and multitude therapeutics inc announce global development and commercialization agreement on first in class adc drug candidate targeting tissue factor was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News